Molecular Mechanisms and Carotid Atherosclerosis
关键词
抽象
描述
Diabetes Mellitus (DM) leads to increased vulnerability for plaque disruption and mediates increased incidence and severity of clinical events. Inflammation, particularly in diabetes, plays a central role in the cascade of events that result in plaque erosion and fissuring. There is emerging evidence that the methylase system might be involved in both initial stage and progression of atherosclerosis. Moreover, the methylase system might be involved in inflammatory/oxidative stress pathway, involved for activation of nuclear factor kappa B (NF-KB), and other proteins linked to over inflammation/oxidative stress. Although it has been demonstrated that diabetes may up regulate these inflammatory/oxidative pathway, still no evidence exists about the potential role of methylase system in the evolution of atherosclerotic plaques of diabetic patients. Conversely, less data have been reported about the possible modulation of these pathways by hypoglycemic drugs as oral metfromin. However, in the present study authors hypothesized that by increasing methylase activity, diabetes may enhance the inflammatory potential of atherosclerotic plaques favoring instability. Therefore, authors designed this study to identify differences in inflammatory infiltration as well as methylase activity between carotid plaques of asymptomatic diabetic and non diabetic (normoglycemics) patients. Because experimental and pathological studies suggest that activation of methylase system might control inflammation/oxidative stress, the present study also evaluated the effect of the metformin on methylase activity in carotid plaques of diabetic patients.
日期
最后验证: | 04/30/2019 |
首次提交: | 05/21/2019 |
提交的预估入学人数: | 05/21/2019 |
首次发布: | 05/23/2019 |
上次提交的更新: | 05/21/2019 |
最近更新发布: | 05/23/2019 |
实际学习开始日期: | 12/31/2014 |
预计主要完成日期: | 12/31/2016 |
预计完成日期: | 12/31/2017 |
状况或疾病
干预/治疗
Drug: patients with diabetes mellitus (DM) plus metformin
相
手臂组
臂 | 干预/治疗 |
---|---|
normoglycemics In this cohort will be enrolled 30 normoglycemics patients affected by carotid artery atherosclerotic and evidence of atherosclerotic plaque causing an endolumninal stenosis > 60%. These patients will receive a surgical intervention to remove the atherosclerotic plaque and to revascularize the obstructed coronary artery vessel. | |
patients with diabetes mellitus (DM) In this cohort will be enrolled 23 DM patients affected by carotid artery atherosclerotic and evidence of atherosclerotic plaque causing an endolumninal stenosis > 60%. These patients will receive a surgical intervention to remove the atherosclerotic plaque and to revascularize the obstructed coronary artery vessel. | |
patients with diabetes mellitus (DM) plus metformin In this cohort will be enrolled 23 DM patients affected by carotid artery atherosclerotic and evidence of atherosclerotic plaque causing an endolumninal stenosis > 60%. These patients will receive a surgical intervention to remove the atherosclerotic plaque and to revascularize the obstructed coronary artery vessel. These patients were treated before the surgical intervention by metformin 1000 mg daily. | Drug: patients with diabetes mellitus (DM) plus metformin Patients in the third study cohort will receive for 4 months a 1000 mg metformin oral therapy before to practice surgical intervention for carotid artery obstruction. |
资格标准
有资格学习的年龄 | 18 Years 至 18 Years |
有资格学习的性别 | All |
取样方式 | Non-Probability Sample |
接受健康志愿者 | 是 |
标准 | Inclusion Criteria: - evidence of carotid artery atherosclerosis with endoluminal stenosis > 60%; - aged >18 years. - aged <75 years Exclusion Criteria: - insulin dependent DM; - absence of carotid artery atherosclerosis with endoluminal stenosis > 60%; - contraindication to receive a carotid artery revascularization treatment; --contraindication to receive metformin treatment; - neoplastic diseases; |
结果
主要结果指标
1. methylase status [12 months]